ID1 and breast carcinoma: The systemic delivery of an antisense molecule to ID1, peptide conjugate antisense oligonucleotide (ID1-PCAO), can effectively reduce ID1 protein levels in tumor endothelium to inhibit primary tumor growth and metastatic spread of lung cancer and breast cancer.